ArticleThoracic cancer2024

The efficacy of almonertinib and anlotinib combination therapy for advanced non-small-cell lung cancer patients who continued to experience cancer progression during third-generation EGFR-TKI treatment: a retrospective study.

Yu Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.